Dr. Mewawalla's work pairs clinical trials with real-world evidence and quality improvement so that advances in CAR T-cell therapy and bispecific antibodies reach patients safely.
A multicenter real-world analysis examining outcomes with CAR T-cell therapy and bispecific antibodies following prior belantamab exposure, addressing an important question in post-BCMA treatment sequencing.
An AHN implementation study demonstrating how standardized training and monitoring pathways can support safe bispecific-antibody administration across community infusion centers.
Real-world evidence evaluating the safety and effectiveness of belantamab mafodotin in heavily pretreated relapsed/refractory multiple myeloma.
A multicenter study examining real-world talquetamab outcomes in heavily pretreated patients, including patients with prior BCMA-directed treatment.
A multicenter real-world comparison of DVRd and VRd in transplant-eligible newly diagnosed multiple myeloma.
A large real-world analysis of changing treatment patterns and survival in AL amyloidosis, including outcomes during the daratumumab era.
A review of patient-reported outcomes, real-world data, digital health, treatment sequencing, and equity-conscious monitoring in relapsed/refractory myeloma.
Multiple myeloma and cellular therapy trials are available through the Allegheny Health Network Cancer Institute, where Dr. Mewawalla serves as principal or sub-investigator. Patients and referring physicians are welcome to ask about current options.
Helped lead a clinical workflow redesign associated with a reduction in institutional CAR T-cell hospitalization from approximately 21 to 7 days, an institutional quality-improvement outcome (not a published trial result).
Standardized step-up dosing and monitoring pathways that support bispecific antibody administration closer to home.
Contributed to development of a comprehensive transplant and cellular therapy program within a FACT-accredited program.
Active member of the U.S. Myeloma Innovations Research Collaborative (USMIRC), a multi-center group producing real-world evidence across leading U.S. cancer centers. Interested in a multi-center analysis, trial collaboration, or real-world data partnership in myeloma or cellular therapy? She welcomes the conversation.
The full, continually updated list of publications is available on Google Scholar, PubMed, and ORCID.